Comparative Pharmacology
Head-to-head clinical analysis: PROQUIN XR versus ZAGAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROQUIN XR versus ZAGAM.
PROQUIN XR vs ZAGAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
Sparfloxacin, a fluoroquinolone antibiotic, inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby blocking DNA replication and transcription.
500 mg orally once daily with food.
600 mg intravenously once daily or 600 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 10-14 hours in patients with normal renal function (CrCl >80 mL/min). Extended half-life may occur in renal impairment, necessitating dose adjustment.
10-12 hours; prolonged in renal impairment
Primarily renal excretion of unchanged drug (~60-80%) via glomerular filtration and tubular secretion. Biliary/fecal excretion accounts for approximately 20-35%, with a small portion as metabolites.
Renal: 60-80% unchanged; biliary/fecal: 10-20%
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic